Gap junction alpha-1 protein (GJA1) (Cx43)

Gap junction alpha-1 protein (GJA1), widely known as Connexin 43 (Cx43), is a principal component of gap junctions and hemichannels in various tissues, most notably the heart, brain, and skin [2, 6]. It forms hexameric channels called connexons; when two connexons from adjacent cells dock, they form a gap junction that allows the direct exchange of ions, metabolites, and small signaling molecules, facilitating synchronized activities like cardiac contraction [11, 15]. In its undocked hemichannel form, Cx43 mediates communication between the cytoplasm and the extracellular space, often releasing paracrine signals such as ATP in response to cellular stress [5, 20]. Dysregulation of Cx43 is linked to numerous pathologies, including cardiac arrhythmias, chronic non-healing wounds, and cancer progression, where it can exhibit complex roles as both a tumor suppressor and a facilitator of metastasis [4, 19, 21]. Therapeutic interventions targeting Cx43 include peptidomimetics like αCT1, which stabilizes gap junctions to improve wound healing, and hemichannel blockers like tonabersat, which aim to reduce inflammatory signaling in neurological and vascular diseases [10, 22].

Other names

GJA1CX43GJALGap junction 43 kDa heart proteinConnexin-43AVSD3EKVP3HLHS1PPKCACMDREKVPHSSODDDODDSDTY3

Connexin 43-targeted therapies function through several distinct mechanisms: gap junction modulation, hemichannel inhibition, and disruption of protein-protein interactions. Peptidomimetics like αCT1 (Granexin) disrupt the binding of Cx43 to the PDZ2 domain of Zonula occludens-1 (ZO-1), which promotes the assembly of larger, more stable gap junction plaques and enhances intercellular communication [4, 10, 18]. Gap junction openers like Danegaptide and Rotigaptide maintain electrical and chemical coupling between cells during metabolic stress or ischemia [15, 22]. Conversely, hemichannel blockers such as Tonabersat and mimetic peptides (Gap26, Gap27) prevent the aberrant opening of undocked connexons, thereby inhibiting the release of pro-inflammatory danger signals like ATP and glutamate into the extracellular space [19, 21, 22]. Additionally, some peptides like JM2 interfere with the microtubule-dependent trafficking of Cx43 to the plasma membrane [3].